Friday, June 27, 2025 9:32:39 AM
Agreed.
While uplisting from the OTC markets to a major exchange like Nasdaq offers increased visibility, liquidity, and access to institutional investors, there are several reasons why Elite may choose to remain on the OTC markets.
OTC markets have significantly lower listing and ongoing compliance costs compared to Nasdaq, which requires substantial fees and resources to meet and maintain stricter financial, governance, and reporting standards.
OTC-listed companies face less stringent regulatory and disclosure requirements, reducing the administrative and legal overhead associated with public company compliance on a national exchange.
Companies on the OTC markets have more flexibility in their operations and financial reporting, as they are not subject to the same level of scrutiny and governance as Nasdaq-listed firms.
Uplisting is not guaranteed to result in higher share prices or increased liquidity, and the process itself can be costly and time-consuming.
Companies that uplist before they are operationally or financially ready may struggle to meet ongoing requirements, risking delisting or reputational harm.
While uplisting from the OTC markets to a major exchange like Nasdaq offers increased visibility, liquidity, and access to institutional investors, there are several reasons why Elite may choose to remain on the OTC markets.
OTC markets have significantly lower listing and ongoing compliance costs compared to Nasdaq, which requires substantial fees and resources to meet and maintain stricter financial, governance, and reporting standards.
OTC-listed companies face less stringent regulatory and disclosure requirements, reducing the administrative and legal overhead associated with public company compliance on a national exchange.
Companies on the OTC markets have more flexibility in their operations and financial reporting, as they are not subject to the same level of scrutiny and governance as Nasdaq-listed firms.
Uplisting is not guaranteed to result in higher share prices or increased liquidity, and the process itself can be costly and time-consuming.
Companies that uplist before they are operationally or financially ready may struggle to meet ongoing requirements, risking delisting or reputational harm.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
